Kirbi Kersey, NP
Nurse Practitioner · London, KYNPI 1851770051
Payments from drug & device makers
Across 34 payments — averaging $18.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Seqirus USA Inc$154
- Genentech USA, Inc.$93
- AbbVie$84
- Lilly USA, LLC$62
- AstraZeneca$36
- Merck$35
- plus $163 from 10 others
What the payments were for
- Food & beverage$627100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Seqirus USA Inc | 1 | $154 |
| Genentech USA, Inc. | 10 | $93 |
| AbbVie | 5 | $84 |
| Lilly USA, LLC | 4 | $62 |
| AstraZeneca | 2 | $36 |
| Merck | 2 | $35 |
| Otsuka America Pharmaceutical, Inc. | 1 | $27 |
| Amgen | 1 | $19 |
| Novo Nordisk | 1 | $18 |
| Lundbeck LLC | 1 | $16 |
| Ironshore Pharmaceuticals Inc. | 1 | $15 |
| Sanofi-aventis U.S. LLC | 1 | $14 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
| Johnson & Johnson | 1 | $14 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $13 |
| Neurocrine Biosciences, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$627 in reported general payments places this provider in the 60th percentile of 1,918 nurse practitioner providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ventolin HfaAlbuterol Sulfate | 29 | $1,663 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 24 | $501 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 22 | $209 |
| Cefdinir | 16 | $175 |
| Cephalexin | 38 | $172 |
| Mupirocin | 22 | $122 |
| Prednisone | 80 | $115 |
| Doxycycline Hyclate | 26 | $114 |
| Ondansetron OdtOndansetron | 12 | $82 |
| Diclofenac Sodium | 14 | $58 |
| Tizanidine Hcl | 12 | $31 |
| Fluconazole | 11 | $24 |
| Metformin Hcl | 11 | $16 |
| Sertraline Hcl | 11 | $8 |
Paid to pharmacies, not to this prescriber.
Other nurse practitioner in London
- Rachael BradfordLexington$447K
- Tara MuddLouisville$243K
- Lee HaasLouisville$95K
- Ashley KnableLouisville$86K
- Christina BenningerLouisville$81K
- Courtney BowlingCampbellsville$47K
- Rebecca BraunerLouisville$40K
- Scott SeitzWinchester$34K
- Kristen KreinestEdgewood$34K
- Lillian ArgentEdgewood$33K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.